Ligand Pharmaceuticals Reaffirms FY24 Adj. EPS $4.25-$4.75 Vs $4.44 Est.; Revenue $130M-$142M Vs $137.680M Est.
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals has reaffirmed its fiscal year 2024 adjusted earnings per share (EPS) guidance to be in the range of $4.25 to $4.75, compared to the consensus estimate of $4.44. The company also expects revenue to be between $130 million and $142 million, versus the estimated $137.680 million.
May 07, 2024 | 9:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals reaffirms its FY24 EPS and revenue guidance, closely aligning with analyst estimates.
Reaffirming guidance that aligns closely with analyst estimates typically instills confidence in investors, suggesting that the company is on track to meet or potentially exceed expectations. This can lead to positive sentiment and potentially an uptick in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100